Chong Kun Dang has announced the preclinical study results of the anti-cancer double antibody bio new drug "CKD-702" at an international academic conference, raising expectations for the birth of a new global innovation drug.
Chong Kun Dang presented the results of its preclinical study on the new drug CKD-702 at the annual conference of the American Association for Cancer Research (AACR), which will run online for three days from June 22.
The annual conference of the AACR is the world's largest cancer research academic event in which more than 25,000 researchers, clinicians and health industry workers from about 80 countries participate each year to share the latest insights on cancer research.
The preclinical study was conducted by CKD-702 solo therapy in non-small cell lung cancer animal models to check the anticancer effect and action mechanism.
The results show that CKD-702 has an anti-cancer effect that simultaneously inhibits c-Met (hepatocyte growth factor receptor) and EGFR (epidermal growth factor receptor), which are essential for cancer growth in cancer cells. In particular, the company stressed that the anti-cancer effect was also found to be excellent in animal models that were resistant to c-Met, EGFR targeted agents (TKI).
CKD-702 combines c-Met and EGFR at the same time to block cancer cell proliferation signals and reduce the number of two receptors to show anticancer effects.
It is also expected to be a bio-new drug that can solve the resistance problem of targeted anti-cancer drugs with three mechanisms of action, including creating an antibody-dependent cellular cytotoxicity (ADCC) that helps immune cells perform a killing function on cancer cells.
Currently, non-small cell lung cancer is currently undergoing Phase 1 clinical trials in Korea as an indication, and plans to expand its coverage to stomach, colon and liver cancer in the future to carry out global clinical trials.
"The double antibodies, which are attracting attention as the next-generation anti-cancer drug, have significant implications for the preclinical results of the CKD-702 because there is only one approved drug in the world," a Chong Kun Dang official said.
